EA
NKTR icon

Emerald Advisers’s Nektar Therapeutics NKTR Stock Holding History

Emerald Advisers’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$27.2M Sell
390,158
-4,446
-1% -$325K 0.64% 72
2026
Q1 		$28.4M Buy
394,604
+10,262
+3% +$584K 0.9% 44
2025
Q4 		$16.2M Buy
384,342
+61,096
+19% +$3.42M 0.5% 90
2025
Q3 		$18.4M Buy
+323,246
New +$10.7M 0.59% 70

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
TSC
Two Seas Capital Rye, New York $5.05B AUM 164.99% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Emerald Advisers's NKTR Position: Q2 2026 in Review

Emerald Advisers reduced its Nektar Therapeutics (NKTR) stake by 1.1% in Q2 2026, selling an estimated $325K and leaving 390,158 shares worth $27.2M. The position accounts for 0.64% of the portfolio, ranked #72.

Emerald Advisers first reported a position in NKTR in Q3 2025 and has held it in 4 quarters since. The position peaked at $28.4M in Q1 2026. 240 funds tracked by Wall St. Rank hold NKTR as of Q2 2026.

  • Emerald Advisers held 390,158 shares of Nektar Therapeutics worth $27.2M as of Q2 2026.
  • Emerald Advisers sold 4,446 Nektar Therapeutics shares in Q2 2026, an estimated $325K.
  • Nektar Therapeutics made up 0.64% of Emerald Advisers's portfolio in Q2 2026, its #72 holding.
  • Emerald Advisers first reported a position in Nektar Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • Emerald Advisers's Nektar Therapeutics position peaked at $28.4M in Q1 2026.
  • 240 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2026.

Based on Emerald Advisers's 13F filing for Q2 2026, filed 5 Aug 2026.